Efetividade de Materiais Educacionais para Profissionais de Saúde e População geral Alvo enquanto Medidas Adicionais de Minimização de Risco para Vabysmo®, Eylea® e Lucentis® - O Estudo MARVEL

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Assessment of risk minimisation measure implementation or effectiveness

Non-interventional study

• Non-interventional study design:
  Cohort

Population studied

• Age groups:
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Estimated number of subjects:
  500

Study design details

• Main study objective:
  The objective of the study is to evaluate the effectiveness of educational materials designed to healthcare professionals and patients used as additional risk minimisation measures for Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab).
• Outcomes:
  For healthcare professionals and the general population target, evaluate: - Receiving and viewing educational materials used as additional risk minimisation measures for Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab). - The level of knowledge of the key messages described in the educational materials used as additional risk minimisation measures for Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab).
• Data analysis plan:
  Descriptive statistics will be used. Frequency distributions with 95% confidence intervals (CI) will be calculated for all responses. The data will be stratified by target group: health care professionals and patients/caregivers and by medicine.